David Michael Madden
Fondateur chez Narrow River Management LP
Profil
David Michael Madden is the founder of Narrow River Management LP.
He is currently an Independent Director at Navitor Pharmaceuticals, Inc. He has formerly served as the Chief Executive Officer & Director at River Vision Development Corp., President, Chief Executive Officer & Director at Selectide Corp., Chairman at Adolor Corp., Chairman at Dicerna Pharmaceuticals, Inc., Director at Royalty Pharma AG, Managing Member at Pharmaceutical Partners LLC, and Director at Hospital for Special Surgery.
Mr. Madden holds an MBA degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from Union College (New York).
Postes actifs de David Michael Madden
| Sociétés | Poste | Début |
|---|---|---|
Narrow River Management LP
 Narrow River Management LP Pharmaceuticals: MajorHealth Technology Narrow River Management LP operates as a investment management company, which focuses on equity investments in the pharmaceutical industry. The company was founded by David M. Madden and is headquartered in New York, NY. | Fondateur | - |
Navitor Pharmaceuticals, Inc.
 Navitor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de David Michael Madden
| Sociétés | Poste | Fin |
|---|---|---|
| DICERNA PHARMACEUTICALS, INC. | Président | 23/01/2019 |
River Vision Development Corp.
 River Vision Development Corp. BiotechnologyHealth Technology River Vision Development Corp. develops novel protein therapies. The firm provides therapy for the treatment of graves orbitopathy which is a condition in which an autoimmune response is mounted against tissues behind the eye, causing inflammation, tissue proliferation and excess production of extracellular matrix. The company was founded in 2011 and is headquartered in New York, NY. | Directeur Général | 01/05/2017 |
Adolor Corp.
 Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Président | 01/12/2011 |
| Royalty Pharma AG | Directeur Général | 01/03/2003 |
Pharmaceutical Partners LLC
 Pharmaceutical Partners LLC Financial ConglomeratesFinance Pharmaceutical Partners LLC is an investment holding private company based in New York, NY. | Corporate Officer/Principal | 01/10/2000 |
Formation de David Michael Madden
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| Union College (New York) | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Adolor Corp.
Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Health Technology |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
River Vision Development Corp.
River Vision Development Corp. BiotechnologyHealth Technology River Vision Development Corp. develops novel protein therapies. The firm provides therapy for the treatment of graves orbitopathy which is a condition in which an autoimmune response is mounted against tissues behind the eye, causing inflammation, tissue proliferation and excess production of extracellular matrix. The company was founded in 2011 and is headquartered in New York, NY. | Health Technology |
Navitor Pharmaceuticals, Inc.
Navitor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA. | Health Technology |
Selectide Corp.
 Selectide Corp. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Selectide Corp. is a pharmaceutical research firm. The company is based in Tucson, AZ. The company was founded by Stephen Ralfe Evans-Freke. Selectide was acquired by Marion Merrell Dow, Inc. on January 27, 1995 for $58 million. | Commercial Services |
| Royalty Pharma AG | Distribution Services |
Hospital for Special Surgery
 Hospital for Special Surgery Hospital/Nursing ManagementHealth Services Hospital for Special Surgery provides healthcare services. Its services include orthopedic, rheumatology, and rehabilitation specific surgery services. The company was founded by James A. Knight and Robert M. Hartley in 1863 and is headquartered in New York, NY. | Health Services |
Pharmaceutical Partners LLC
Pharmaceutical Partners LLC Financial ConglomeratesFinance Pharmaceutical Partners LLC is an investment holding private company based in New York, NY. | Finance |
Narrow River Management LP
Narrow River Management LP Pharmaceuticals: MajorHealth Technology Narrow River Management LP operates as a investment management company, which focuses on equity investments in the pharmaceutical industry. The company was founded by David M. Madden and is headquartered in New York, NY. | Health Technology |